JDTic

• Target :

  Opioid Receptor|||JAK

• Related Pathways :

  Angiogenesis|||Chromatin/Epigenetic|||Stem Cells|||Neuroscience|||JAK/STAT signaling|||Endocrinology/Hormones|||Tyrosine Kinase/Adaptors|||GPCR/G Protein

• Bioactivity :

  JDTic, a 4-phenylpiperidine derivative distantly related to analgesics like meperidine and ketobemidone and more closely to the mu opioid antagonist alvimopan, exhibits a notably long duration of action, maintaining effects in animals for weeks following a single dose. This duration is not due to irreversible binding to the kappa opioid receptor but rather to altered activity of c-Jun N-terminal kinases. As a highly selective antagonist for the ?-opioid receptor, without influencing the ?- or ?-opioid receptors, JDTic has shown potential in animal studies for producing antidepressant and anxiolytic effects. It also demonstrates promise in treating addiction to substances such as cocaine and morphine, distinguishing itself structurally from other kappa antagonists like norbinaltorphimine.

• Smiles :

  C[C@@]1([C@@H](C)CN(C[C@@H](NC(=O)[C@H]2CC=3C(CN2)=CC(O)=CC3)C(C)C)CC1)C4=CC(O)=CC=C4

• Molecular Formula :

  C28H39N3O3

• Molecular Weight :

  465.63

• Shipping Conditions :

  Cool pack

• Storage Temperature :

  -20°C

• CAS Number :

  361444-66-8